Hiroki Umemiya
Taisho Pharmaceutical Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroki Umemiya.
Bioorganic & Medicinal Chemistry Letters | 2010
Tetsuo Takayama; Hiroki Umemiya; Hideaki Amada; Tetsuya Yabuuchi; Fumiyasu Shiozawa; Hironori Katakai; Akiko Takaoka; Akie Yamaguchi; Mayumi Endo; Masakazu Sato
We have described the synthesis, enzyme inhibitory activity, structure-activity relationships, and proposed binding mode of a novel series of pyrrole derivatives as lymphocyte-specific kinase (Lck) inhibitors. The most potent analogs exhibited good enzyme inhibitory activity (IC(50)s <10nM) for Lck kinase inhibition.
Bioorganic & Medicinal Chemistry Letters | 2010
Tetsuo Takayama; Hiroki Umemiya; Hideaki Amada; Tetsuya Yabuuchi; Takeshi Koami; Fumiyasu Shiozawa; Yusuke Oka; Akiko Takaoka; Akie Yamaguchi; Mayumi Endo; Masakazu Sato
We have identified a novel series of ring-fused pyrazole derivatives as lymphocyte-specific kinase (Lck) inhibitors. The most potent analogs exhibited good enzyme inhibitory activity (IC(50)s <1nM) as well as excellent cellular activity against mixed lymphocyte reaction (MLR) (IC(50)s <1nM).
Drug Research | 2011
Tetsuo Takayama; Akiko Takaoka; Shuya Takahashi; Akiko Takahashi; Hiroki Umemiya; Masakazu Sato
Lymphocyte-specific protein tyrosine kinase (Lck) plays a critical role in T cell activation. In the present study, the effect of a newly synthesized small molecule compound, 7-[2-(dimethylamino)ethoxy]-2-(4-phenoxyphenyl)-9,10-dihydro-4H- pyrazolo[5,1-b] [1,3]benzodiazepine-3-carboxamide (TKM0150) on Lck activity was investigated. TKM0150 inhibited Lck with an 1C50 value of 0.7 nM. To evaluate if TKM0150 is a specific inhibitor of Lck, the activity against several Src (Proto-oncogene tyrosine-protein kinase Src) and non-Src family kinases were assayed. TKM150 inhibited Src family kinases, Src and Csk (c-Src kinase) (with IC50 values of 0.6 nM and 1.7 nM, respectively) as well as Fyn (p59-Fyn) and Lyn (tyrosine-protein kinase Lyn) at a dose of 1 microM; however, it did not inhibit kinase which is a non-Src family kinase in the tyrosine kinase (TK) group, nor kinases in other groups. Then, the anti-inflammtory potential of TKM0150 was evaluated by known experimental models. TKM0150 inhibited the murine mixed lymphocyte reaction (MLR) in vitro with an IC50 value of 0.7 nM, and 2,4,6-trinitro-1-chlorobenzene-induced contact hypersensitivity in vivo at a dose of 0.3 and 1% w/v administered topically. These results indicate that TKM0150 is a specific inhibitor of Lck/Src kinase and can block T cell-mediated responses in vitro and in vivo. Accordingly, TKM0150 would be expected as a drug candidate for treating T cell-mediated disorders including atopic dermatitis.
Bioorganic & Medicinal Chemistry Letters | 2004
Toshio Nakamura; Hiroyuki Kakinuma; Hiroki Umemiya; Hideaki Amada; Noriyuki Miyata; Kazuo Taniguchi; Kagumi Bando; Masakazu Sato
Archive | 2002
Masakazu Sato; Hiroyuki Kakinuma; Hiroki Umemiya; Toshio Nakamura
Archive | 2003
Shiuji Saito; Hiroki Umemiya; Yoichirou Suga; Masakazu Sato; Naoya Kawashima
Archive | 2003
Masakazu Sato; 佐藤 正和; Hiroki Umemiya; 梅宮 広樹; Yuko Matsunaga; 松永 結子; Tetsuo Takayama; 哲男 高山
Archive | 2006
Hiroki Umemiya; Hideaki Amada; Tetsuya Yabuuchi; Takeshi Koami; Fumiyasu Shiozawa; Yusuke Oka; Masakazu Sato
Archive | 2005
Hiroki Umemiya; Tetsuo Takayama; Hideaki Amada; Fumiyasu Shiozawa; Masakazu Sato; Tetsuya Yabuuchi; Hironori Katakai
Archive | 2005
Masakazu Sato; Yuko Matsunaga; Hajime Asanuma; Hideaki Amada; Takeshi Koami; Tetsuo Takayama; Tetsuya Yabuuchi; Fumiyasu Shiozawa; Hironori Katakai; Hiroki Umemiya; Akiko Ikeda